INDOCO REMEDIES Financial Statement Analysis
|
||
The Revenues of INDOCO REMEDIES have increased by 8.30% YoY .
The Earnings Per Share (EPS) of INDOCO REMEDIES has decreased by -8.10 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
INDOCO REMEDIES Last 5 Annual Financial Results
[BOM: 532612|NSE : INDOCO]
Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹1,669 Cr | ₹1,541 Cr | ₹1,242 Cr | ₹1,107 Cr | ₹968 Cr |
Expenses | ₹1,383 Cr | ₹1,215 Cr | ₹1,023 Cr | ₹986 Cr | ₹892 Cr |
Operating Profit (Excl OI) | ₹286 Cr | ₹326 Cr | ₹218 Cr | ₹121 Cr | ₹77 Cr |
Other Income | ₹2.38 Cr | ₹3.42 Cr | ₹9.06 Cr | ₹4.80 Cr | ₹6.70 Cr |
Interest | ₹25 Cr | ₹14 Cr | ₹22 Cr | ₹26 Cr | ₹21 Cr |
Depreciation | ₹71 Cr | ₹79 Cr | ₹73 Cr | ₹71 Cr | ₹72 Cr |
Profit Before Tax | ₹193 Cr | ₹237 Cr | ₹132 Cr | ₹29 Cr | ₹-9.31 Cr |
Profit After Tax | ₹142 Cr | ₹155 Cr | ₹93 Cr | ₹24 Cr | ₹-2.90 Cr |
Consolidated Net Profit | ₹142 Cr | ₹155 Cr | ₹93 Cr | ₹24 Cr | ₹-2.90 Cr |
Earnings Per Share (Rs) | ₹15.44 | ₹16.80 | ₹10.10 | ₹2.62 | ₹-0.32 |
PAT Margin (%) | 8.53 | 10.05 | 7.49 | 2.18 | -0.30 |
ROE(%) | 14.72 | 18.50 | 12.85 | 3.60 | -0.43 |
ROCE(%) | 17.48 | 23.03 | 15.67 | 5.78 | 1.23 |
Total Debt/Equity(x) | 0.31 | 0.27 | 0.34 | 0.39 | 0.45 |
Key Financials |
||
Market Cap | : | ₹ 3,110.8 Cr |
Revenue (TTM) | : | ₹ 1,795.8 Cr |
Net Profit(TTM) | : | ₹ 100.8 Cr |
EPS (TTM) | : | ₹ 10.9 |
P/E (TTM) | : | 30.9 |
Industry Peers & Returns | 1W | 1M | 1Y |
INDOCO REMEDIES | 2.7% | -0.6% | 2.7% |
SUN PHARMACEUTICAL INDUSTRIES | 0.3% | -7.5% | 53.9% |
CIPLA | 1.1% | -4.8% | 56.4% |
DR REDDYS LABORATORIES | 1.6% | 1.6% | 27.6% |
ZYDUS LIFESCIENCES | 5.2% | -0.2% | 90.1% |
DIVIS LABORATORIES | -1.9% | 10.7% | 21.4% |
MANKIND PHARMA | -2.3% | 0.1% | NA |
TORRENT PHARMACEUTICALS | 1.6% | 2% | 61.8% |
LUPIN | 2.4% | 2% | 132.5% |
INDOCO REMEDIES Revenues
[BOM: 532612|NSE : INDOCO]
Y-o-Y | 8.30 % |
5 Yr CAGR | 14.57 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹1,669 Cr | 8.30 | |
Mar2022 | ₹1,541 Cr | 24.10 | |
Mar2021 | ₹1,242 Cr | 12.19 | |
Mar2020 | ₹1,107 Cr | 14.26 | |
Mar2019 | ₹968 Cr | - |
INDOCO REMEDIES Operating Profit
[BOM: 532612|NSE : INDOCO]
Y-o-Y | -12.32 % |
5 Yr CAGR | 38.99 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹286 Cr | -12.32 | |
Mar2022 | ₹326 Cr | 49.43 | |
Mar2021 | ₹218 Cr | 80.67 | |
Mar2020 | ₹121 Cr | 57.66 | |
Mar2019 | ₹77 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -19.04 % |
5 Yr CAGR | 21.33 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 17.14% | -19.04 | |
Mar2022 | 21.17% | 20.35 | |
Mar2021 | 17.59% | 61.08 | |
Mar2020 | 10.92% | 38.05 | |
Mar2019 | 7.91% | - |
INDOCO REMEDIES Profit After Tax
[BOM: 532612|NSE : INDOCO]
Y-o-Y | -8.11 % |
5 Yr CAGR | Positive |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹142 Cr | -8.11 | |
Mar2022 | ₹155 Cr | 66.37 | |
Mar2021 | ₹93 Cr | 285.81 | |
Mar2020 | ₹24 Cr | Positive | |
Mar2019 | ₹-2.90 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -15.12 % |
5 Yr CAGR | Positive |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 8.53 % | -15.12 | |
Mar2022 | 10.05 % | 34.18 | |
Mar2021 | 7.49 % | 243.58 | |
Mar2020 | 2.18 % | Positive | |
Mar2019 | -0.3 % | - |
INDOCO REMEDIES Earnings Per Share (EPS)
[BOM: 532612|NSE : INDOCO]
Y-o-Y | -8.10 % |
5 Yr CAGR | Positive |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹15 | -8.10 | |
Mar2022 | ₹17 | 66.34 | |
Mar2021 | ₹10 | 285.50 | |
Mar2020 | ₹2.62 | Positive | |
Mar2019 | ₹-0.32 | - |
INDOCO REMEDIES Return on Capital Employed (ROCE)
[BOM: 532612|NSE : INDOCO]
Y-o-Y | -24.10 % |
5 Yr CAGR | 94.16 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 17.48% | -24.10 | |
Mar2022 | 23.03% | 46.97 | |
Mar2021 | 15.67% | 171.11 | |
Mar2020 | 5.78% | 369.92 | |
Mar2019 | 1.23% | - |
INDOCO REMEDIES Share Price vs Sensex
Current Share Price | : | ₹337.4 |
Current MarketCap | : | ₹ 3,110.8 Cr |
Updated EOD on | : | May 03,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
INDOCO REMEDIES | 2.7% |
-0.6% |
2.7% |
SENSEX | -0.6% |
0.3% |
21.8% |
INDOCO REMEDIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE MIDSMALLCAP | 1.4% | 8.6% | 66.5% |
S&P BSE HEALTHCARE | 0.8% | 1.5% | 55.8% |
S&P BSE ALLCAP | 0.4% | 3.7% | 40% |
S&P BSE SMALL CAP | 0.2% | 9.3% | 64.7% |
You may also like the below Video Courses
FAQ about INDOCO REMEDIES Financials
How the annual revenues of INDOCO REMEDIES have changed ?
The Revenues of INDOCO REMEDIES have increased by 8.30% YoY .
How the Earnings per Share (EPS) of INDOCO REMEDIES have changed?
The Earnings Per Share (EPS) of INDOCO REMEDIES has decreased by -8.10 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs